Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Author(s) -
James Bainbridge,
Manjit Mehat,
Venki Sundaram,
Scott Robbie,
Susie E. Barker,
Caterina Ripamonti,
Anastasios Georgiadis,
Freya M. Mowat,
Stuart G. Beattie,
Peter J. Gardner,
Kecia L. Feathers,
Vy Luong,
Suzanne Yzer,
Kamaljit S. Balaggan,
Ananth C. Viswanathan,
Thomy de Ravel,
Ingele Casteels,
Graham E. Holder,
Nick Tyler,
Fred W. Fitzke,
Richard G. Weleber,
Marko Nardini,
Anthony T. Moore,
Debra A. Thompson,
Simon M. PetersenJones,
Michel Michaelides,
L. Ingeborgh van den Born,
Andrew Stockman,
Alexander J. Smith,
Gary S. Rubin,
Robin R. Ali
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1414221
Subject(s) - rpe65 , medicine , genetic enhancement , retinal , electroretinography , ophthalmology , visual acuity , erg , cis trans isomerases , retina , retinal degeneration , retinal pigment epithelium , gene , neuroscience , biology , genetics , peptidylprolyl isomerase , isomerase
Mutations in RPE65 cause Leber's congenital amaurosis, a progressive retinal degenerative disease that severely impairs sight in children. Gene therapy can result in modest improvements in night vision, but knowledge of its efficacy in humans is limited.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom